Taiba Middle East

What Taiba Middle East does

Taiba Middle East is a privately held pharmaceutical company, founded in 1980 in Muscat, Sultanate of Oman, that markets, distributes and commercializes orphan and rare-disease medicines across the Middle East and Africa. It is positioned as the first and longest-standing rare-disease distributor in the region, leveraging the high prevalence of genetic and metabolic diseases associated with consanguinity in GCC populations. The company is headquartered under the Taiba Healthcare group (also founded 1980) and operates as Taiba Middle East FZ LLC from a Dubai Free Zone logistics hub.

The company's commercial model combines in-licensing from global biotech firms with full commercialization, regulatory registration, pharmacovigilance and physical distribution. Taiba holds distribution and/or commercialization rights for products including ONPATTRO, GIVLAARI and lumasiran (from Alnylam), ARIKAYCE (from Insmed/Elevar) and Sibnayal (from Advicenne) and maintains long-standing distribution relationships with Aegerion, BioMarin, Genzyme (Sanofi), Lucane, Veloxis and Vertex. Its in-house supply chain includes cold-chain handling, temperature-regulated storage, and import/re-export capabilities through the Dubai Free Zone facility. The company has 100+ registered medicines across the region and 20+ years of Named Patient Sales program experience, enabling early access for patients with unmet medical needs in countries where formal commercial availability is pending.

Taiba generates revenue through multiple streams: one-time licensing income from biotech partners, royalties and transfer-price economics (e.g., the Advicenne deal where Taiba receives transfer price plus royalties), transaction-based Named Patient Sales, and distribution/logistics fees routed through the Dubai hub. Customer segments are primarily ministries of health and public hospital systems in six GCC countries (Saudi Arabia, UAE, Oman, Kuwait, Qatar, Bahrain), with secondary expansion into Egypt and other MENA markets. The company runs field sales, medical affairs and scientific engagement teams in each territory, supported by eight country offices and a central regional headquarters.

Name

Taiba Middle East

Legal name

Taiba Middle East

Website

http://www.taibarare.com

Company type

Private

Founded year

1997

Operating status

Operating

Short description

Taiba Middle East is a privately held, Oman-headquartered pharmaceutical company that has specialized since 1980 in marketing, distributing and commercializing orphan and rare-disease medicines across the GCC, Egypt and broader MENA region on behalf of global biotech partners, supported by an in-house Dubai Free Zone logistics hub.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Rare Disease Medicines)

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

akta.pro secondary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Rare disease medicines
• Orphan drug commercialization
• Pharmaceutical distribution
• Specialty pharma licensing
• Named patient access

Headquarters

HQ city

Muscat/Russayl city

HQ country

Oman

HQ region

Middle East

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Product Commercialization: Commercialization of rare disease and orphan medicines through licensing agreements with biotech companies. They execute commercial strategy including HCP education, medical awareness, market mapping and pharmacovigilance.
2. Named Patient Sales: Supply of medicines to individual patients through Named Patient Sales (NPS) programs in countries where medicines are not yet commercially available, primarily in GCC countries.
3. Distribution Services: Logistics and distribution services for pharmaceutical products through their Dubai Free Zone hub serving the entire Middle East and Africa region.
4. Licensing Royalties: Receiving transfer price and royalties from partners such as Advicenne for Sibnayal commercialization rights in defined territories.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Taiba Middle East markets, distributes, and commercializes orphan and rare disease medicines across the Middle East and Africa. The company sources products through licensing agreements with global biotech firms (Alnylam, Insmed, Advicenne, BioMarin, Genzyme, Vertex, etc.) and supplies them to hospitals, ministries of health, and named patients via an integrated in-house distribution network anchored by a Dubai Free Zone logistics hub.

Product overview

Taiba Middle East is a pharmaceutical company specializing in rare and orphan disease medicines, operating as both a commercialization partner and distributor across the Middle East and Africa. The company's product portfolio centers on innovative RNAi therapeutics (ONPATTRO, GIVLAARI, Lumasiran) and specialty medicines (ARIKAYCE, Sibnayal) sourced through strategic partnerships with global biotech companies. Complementing its pharmaceutical portfolio, Taiba offers a comprehensive suite of services including Named Patient Sales programs for early access, regulatory registration across 100+ medicines, commercialization support, and an in-house distribution network with a logistics hub in Dubai. The company focuses on therapeutic areas including genetic and metabolic diseases, pulmonary diseases, hematology, nephrology, oncology, and gene therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• ONPATTRO (patisiran) RNAi therapeutic for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy; targets and silences TTR messenger RNA to reduce protein accumulation. Distributed by Taiba in Gulf states under partnership with Alnylam Pharmaceuticals.
• GIVLAARI (givosiran) RNAi therapeutic approved for the treatment of acute hepatic porphyria (AHP); reduces amyloid protein production in the liver. Distributed by Taiba in Gulf states under partnership with Alnylam Pharmaceuticals.
• ARIKAYCE (amikacin liposomal inhalation suspension) Treatment for refractory Mycobacterium avium complex (MAC) lung disease; contains the active substance amikacin delivered via inhalation. Marketed and distributed by Taiba in GCC countries under exclusive rights from Insmed.
• Sibnayal Treatment for distal Renal Tubular Acidosis (dRTA); the first distribution agreement for Sibnayal outside Europe. Distributed by Taiba in the Middle East under license from Advicenne.
• Lumasiran Late-stage investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1 (PH1); targets the glycolate oxidase gene to reduce oxalate production. Distributed by Taiba in Gulf states under partnership with Alnylam Pharmaceuticals.
• Named Patient Sales (NPS) Program Early access program enabling patients with unmet medical needs to access medicines before commercial availability in GCC countries and expansion to other Middle East and African countries. Operated by Taiba's medical and commercial teams.
• Regulatory Registration Services Medicine registration across Middle East and Africa with over 100 registered medicines; specialized expertise in orphan and biotech medicine registration for biotech partners.
• Commercialization Services Strategic collaboration and in-licensing from biotech industry; includes HCP education, medical awareness, market mapping, and pharmacovigilance for partner products.
• Distribution and Supply Chain Services In-house distribution network with logistics hub in Dubai Free Zone; handles cold chain products and operates temperature-regulated storage with import and re-export capabilities across the region.
• Pharmacovigilance Services Global regulatory reporting compliance with adverse effects reported within 24 hours; ensures compliance with PV processes and local health authority requirements across the region.

Quantifiable outcome

• 100+ registered medicines across the region
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• AdvicennecoreChannel Partner/ Reseller/ Distributor · 7 August 2022First Sibnayal distribution agreement outside Europe. Taiba receives exclusive marketing rights in defined territories. Advicenne receives transfer price and royalties for amount markedly higher than 50% of future sales. Taiba working on early access program for Sibnayal (treatment for distal Renal Tubular Acidosis).
• Insmed BVcoreChannel Partner/ Reseller/ Distributor · 14 June 2021Commercialization agreement for ARIKAYCE in GCC countries. Insmed is a global biopharmaceutical company on a mission to transform lives of patients with serious and rare diseases.
• Insmed Netherlands BVcoreChannel Partner/ Reseller/ Distributor · 5 October 2020Exclusive rights granted to taiba to market and distribute ARIKAYCE in GCC countries (Saudi Arabia, UAE, Kuwait, Oman, Qatar, Bahrain). Taiba responsible for named patient supply program with intent to commercialize following marketing authorization. ARIKAYCE contains active substance amikacin and has been approved in US, EU, UK, and Japan.
• Elevar TherapeuticsminorChannel Partner/ Reseller/ Distributor · 5 October 2020Cooperation in Middle East - North Africa region for ARIKAYCE distribution. Elevar Therapeutics is a subsidiary of Insmed Incorporated focused on serious and rare diseases.
• Alnylam PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 8 July 2020Distribution Agreement for ONPATTRO and GIVLAARI, the first-ever commercialized RNAi therapeutics, as well as lumasiran for Primary Hyperoxaluria Type 1. The agreement covers Gulf states including Kingdom of Saudi Arabia, Kuwait, Bahrain, Qatar, Oman and the United Arab Emirates. Alnylam Pharmaceuticals is the leading RNAi therapeutics company.
• Aegerion PharmaceuticalsminorChannel Partner/ Reseller/ DistributorOne of the leading multinational companies represented by taiba in the rare disease space.
• BioMarin PharmaceuticalminorChannel Partner/ Reseller/ DistributorLeading multinational biotech company represented by taiba for rare disease medicines.
• Genzyme (Sanofi)minorChannel Partner/ Reseller/ DistributorMajor multinational biotechnology company represented by taiba in the region.
• Lucane PharmaceuticalsminorChannel Partner/ Reseller/ DistributorPharmaceutical company represented by taiba for rare disease portfolio.
• Veloxis PharmaceuticalsminorChannel Partner/ Reseller/ DistributorTransplant medication company represented by taiba in the region.
• Vertex PharmaceuticalsminorChannel Partner/ Reseller/ DistributorLeading cystic fibrosis and rare disease pharmaceutical company represented by taiba.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Swedish Orphan Biovitrum (Sobi): Sobi is a global specialty biopharmaceutical company focused on rare and orphan diseases, directly comparable to Taiba in therapeutic area focus (genetic, metabolic, hematology, immunology) and in operating a model of in-licensing and commercializing niche therapies through dedicated regional infrastructure.
• Recordati Rare Diseases: Recordati's rare disease division specializes in acquiring, registering, and commercializing orphan therapies globally — closely mirroring Taiba's model of partnering with biotech innovators to bring rare disease treatments to underserved markets via dedicated commercial and distribution infrastructure.

Regional players

• Hikma Pharmaceuticals: Jordan-headquartered Hikma is one of the largest MENA-focused pharmaceutical manufacturers and distributors with established GCC and broader regional presence; comparable to Taiba in regional market footprint and broad pharma distribution capabilities, though broader in scope and less concentrated on rare disease.
• Julphar (Gulf Pharmaceutical Industries): UAE-based Julphar is a leading GCC pharmaceutical manufacturer and distributor with regional sales infrastructure across the same markets Taiba serves; comparable as a regional pharma commercial platform, though focused on generics rather than orphan/rare disease specialty.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi-listed SPIMACO is a major Saudi pharmaceutical manufacturer and distributor serving the same GCC end-customers (MoH, hospitals, pharmacies) as Taiba; comparable as a regional pharma distribution peer with overlapping geographic focus.
• Tabuk Pharmaceuticals: Saudi-based Tabuk Pharmaceuticals manufactures and distributes branded generics and specialty medicines across MENA; comparable to Taiba in regional GCC market presence and broad pharma distribution model, though less specialized in orphan drugs.
• Neopharma: UAE-based Neopharma is a regional pharmaceutical manufacturer with GCC distribution operations serving the same healthcare systems and ministries of health that Taiba targets; comparable as a regional pharma peer with overlapping geographic and customer footprint.

Broad incumbents

• Alexion / AstraZeneca Rare Disease: Alexion (now part of AstraZeneca) is a global leader in rare disease commercialization with extensive orphan drug portfolio; comparable to Taiba as a rare disease specialist though vastly larger, vertically integrated, and operating a direct-to-market model globally.

Emerging players

• Amryt Pharma (Chiesi Rare Diseases): Amryt Pharma, now part of Chiesi's rare disease franchise, was a specialty pharma company developing and commercializing treatments for rare and orphan diseases; comparable to Taiba in therapeutic focus on metabolic and genetic rare diseases with a licensing-led business model.

Others

• Saudi Pharmaceutical Industries & Medical Appliances (different name, see SPIMACO): Removed for redundancy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/taiba-middle-east
• Xtwitter.com/taibaME
• Facebookfacebook.com/taibaME
• Instagraminstagram.com/taibaME

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taiba Middle East